Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF)
$ 11.7 0 (0%) Market Cap: 121.08 Mil Enterprise Value: 162.23 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 19/100

Santhera Pharmaceuticals Holding AG Investor Conference Call - Looking Ahead to 2022 Transcript

Dec 08, 2021 / 02:00PM GMT
Release Date Price: $14
Dario Eklund
Santhera Pharmaceuticals Holding AG - CEO

Good afternoon and good morning, everyone. Thank you for joining today's webcast. Let me start with first introducing our team that's on the call today. Joining me today is Laura Pfeifer-Rossi. She's a partner and equity research analyst from Octavian, a specialized Swiss equity research, brokerage and corporate finance advisory company. She'll be our moderator today for a part of this session.

And from my team here at Santhera, we have Andrew Smith, our CFO; as well as Shabir Hasham, who's our global program lead for vamorolone and he's joining us from his home in London. As an eventful year comes to an end, we want to give you a snapshot of what -- where Santhera stands today and discuss our strategies, plans and goals going forward into 2022 and beyond.

But first to start, I'd like to remind you of where Santhera stood in the late summer of 2020 last year. Our Phase III trial, called SIDEROS had failed and the lead platform for Duchenne muscular dystrophy was discontinued. We had no material pipeline but only a sublicense option

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot